Study Evaluating Patients With Cystinuria

Phase 2

Withdrawn

• Conditions: Cystinuria
• Interventions: Drug: ADV7103; Drug: Standard of Care

• Registration Number: NCT04137978
• Lead Sponsor: Advicenne Pharma

Brief Summary

This is an open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and acceptability of alkalising treatments at long-term in patients with cystinuria.

Detailed Description

B14CS study is an extension study which follows the B12CS-B13CS study. Patients who have participated in B12CS-B13CS Study will have the possibility to switch to B14CS Study for a long-term treatment period (2 year-period).

The B14CS Study is an open-label long-term study and including 2 types of cohorts.

* ADV7103 Cohort: Cohort of patients who will have completed either B12CS or B13CS Study. Following an optional titration period (for B12CS Study subjects), all patients will be maintained at their ADV7103 optimal dose for a 2-year-period.

* SoC Cohort: Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period. This cohort is designed in order to contextualize the safety, tolerability and efficacy of the long-term ADV7103 treatment.

The B14CS Study will be composed of 3 periods (more detailed hereafter):

* Lead-in Period: Period of 3 weeks, during which the treatment (ADV7103 or SoC) will be taken at the optimal dose as previously defined (Maintenance Phase). The Lead-in Period can include a Titration Phase, for ADV7103 B12CS Cohort only, in order to define the individual optimal dose of ADV7103 for the patients of this cohort;

* Assessment Period: Period of 7 days to evaluate the effect of study products (ADV7103 and SoC) at the optimal dose;

* Follow-up Period: Period of 23 months to evaluate the effects of the study products (ADV7103 and SoC) at long-term.

Study Timeline

• Study First Submitted: 2019-10-18
• Study First Submitted QC: 2019-10-23
• Study First Posted: 2019-10-24
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-08
• Last Update Posted: 2024-03-12
• Study Start: 2024-05-01
• Primary Completion: 2025-06
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• For ADV7103 cohort:

  1. Patient who has participated to and completed the previous B12CS Study or B13CS Study.
  2. Patient for whom the safety and tolerability of ADV7103 were satisfactory during B12CS Study or B13CS Study.
  3. Female patient of childbearing potential (defined by the Clinical Trial Facilitation Group (CTFG) as woman fertile, following menarche until becoming post-menopausal unless permanently sterile*) using an acceptable effective birth control method** and having a negative pregnancy test at the inclusion, or a woman postmenopausal*** or a woman surgically sterilized*.
  4. Patient and/or parents or legal representative(s) who is(are) willing and able to participate in the study, to understand and to comply with study procedures for the entire length of the study.
  5. Patient or parents or legal representative(s) who has(have) provided a signed written informed consent.
  6. Patient of ≤17 Patient of ≤17 years of age for whom the assent has been collected or has been tried to be collected.
  7. Patient who is affiliated to a social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research.

For Standard of Care cohort:

1. Patient who has a diagnosis of cystinuria based on medical diagnosis (at least one previous or current episode of calculus of cystine, and/or one previous or current episode of cystine crystalluria) or on genetic diagnosis (only for patients of Subset 4).
2. Patient treated with an alkalising treatment at a well-adapted dose (defined as a daily dose deemed by the investigator aiming to maintain overtime urinary pH value ≥ 7.0 and/or compatible with an acceptable safety profile and/or patient's constraints or compliance).
3. Patient male or female, including child aged between 6 months and 17 years old and adult aged ≥ 18 years old up to 70 years old.
4. Female patient of childbearing potential (defined by the Clinical Trial Facilitation Group (CTFG) as woman fertile, following menarche until becoming post-menopausal unless permanently sterile*) using an acceptable effective birth control method** and having a negative pregnancy test at the inclusion, or a woman postmenopausal*** or a woman surgically sterilized*.
5. Patient and/or parents or legal representative(s) who is(are) willing and able to participate in the study, to understand and to comply with study procedures for the entire length of the study.
6. Patient or parents or legal representative(s) who has/have provided a signed written informed consent.
7. Patient of ≤17 years of age for whom the assent has been collected or has been tried to be collected.
8. Patient who is affiliated to a social health insurance system and/or in compliance with the recommendations of the national law in force relating to biomedical research.

Exclusion Criteria

• For ADV7103 cohort:

  1. Patient who has not participated to B12CS study or B13CS study
  2. Patient for whom any safety issue could contraindicate her/his participation to the extension study

For Standard of Care cohort:

1. Patient that is receiving the second line therapy -- cystine chelating agents (sulfhydryl compounds).
2. Patient who presents kalaemia > 5.0 mmol/L.
3. Patient who presents a moderate or severe renal impairment (estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2 according to Schwartz formula for the children and both MDRDs and CKD-EPI for adults).
4. Patient who presents - barring the study disease - any previous or concurrent medical condition or any laboratory or clinical findings or any other condition that in the opinion of the investigator would be negatively affected by the study product or that would affect the study product or that precludes his participation, e.g. uncontrolled diabetes mellitus, adrenal insufficiency, cardiac impairment, repeated infections, metabolic alkalosis, chronic diarrhoea.
5. Female patient who is pregnant or breast-feeding.
6. Patient who cannot stop potassium sparing diuretics (e.g. antagonists of aldosterone as such spironolactone, canrenoate and eplerenone, amiloride, triamterene), angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, tacrolimus, potassium desodic salts.
7. Patient who received any medication that could interfere with the study treatment within 4 weeks before the inclusion in the study, including angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, tacrolimus, potassium desodic salts, antibiotics.
8. Patient who received potassium sparing diuretics 6 weeks before the inclusion in the study.
9. Patient who is admitted to hospital in emergency settings.
10. Patient who participated in a clinical trial within the last 3 months before enrolment.
11. Patient who is at risk of non-compliance in the judgment of the investigator.
12. Patient who could present any other condition, which in the opinion of the investigator, would preclude participation in the study.
13. Patient who cannot be contacted in case of emergency.
14. Patient under any administrative or legal supervision.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ADV7103	ADV7103	Patients receive ADV7103 twice a day at optimal dose. Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. Other Names: • Potassium Citrate and Potassium Bicarbonate
Standard of care comparator	Standard of Care	Alkalinising treatment (SoC) taken at the usual dose and frequency

Primary Outcome Measures

Name	Time	Method
Percentage of urinary pH values ≥ 7.0 during 24h on Day 7 (after ADV7103 treatment period)	7 Days	To evaluate the safety and the tolerability of ADV7103 and standard of care (SoC) after a long-term treatment.

Trial Locations

Locations (13)

CHU Reims; 🇫🇷 Reims, France

UZ Leuven, Gasthuisberg Hospital; 🇧🇪 Leuven, Belgium

CHU de Bordeaux - Hôpital Pellegrin; 🇫🇷 Bordeaux, France

Cliniques Universitaires Saint-Luc; 🇧🇪 Brussels, Belgium

Hôpital Necker Enfants Malades; 🇫🇷 Paris, France

Centre Hospitalier Universitaire de Lyon; 🇫🇷 Bron, France

CHU Grenoble; 🇫🇷 Grenoble Cedex, France

CHRU Lille; 🇫🇷 Lille, France

CHU Purpan; 🇫🇷 Toulouse cedex 9, France

CHU Pitié-Salpétrière; 🇫🇷 Paris, France

Hôpital Américain CHU de Reims; 🇫🇷 Reims, France

Hôpital Necker AP-HP; 🇫🇷 Paris, France

Hôpital Ténon - Explorations fonctionnelles Mutlidisciplinaires et INSERM UMR S 1155; 🇫🇷 Paris, France